Bexarotene
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Bexarotene: From Cutaneous T-Cell Lymphoma to Primary Cutaneous B-Cell Lymphoma
One-Sentence Summary
Bexarotene is an oral and topical retinoid X receptor (RXR) agonist, used mainly for cutaneous T-cell lymphoma (CTCL) according to the literature and trial records. The TxGNN model predicts it may be effective for primary cutaneous B-cell lymphoma, but only 2 loosely related clinical trials and general cutaneous lymphoma literature exist, with no B-cell-specific bexarotene data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cutaneous T-cell lymphoma (from literature and trial records; the license fields contain no indication text) |
| Predicted New Indication | Primary cutaneous B-cell lymphoma |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 10 (1 NDA, plus generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. From the literature, bexarotene is a selective RXR agonist that modulates gene expression, cell growth, differentiation and apoptosis. Its efficacy in CTCL is well established, and it is used both orally and topically.
The high TxGNN score most likely reflects the shared “cutaneous lymphoma” neighborhood in the knowledge graph. Primary cutaneous B-cell lymphoma and CTCL are both primary cutaneous lymphomas and appear together in many reviews.
However, the evidence that RXR activation is therapeutically relevant in B-cell lymphomas (marginal zone, follicle center, large B-cell) is lacking. The related trials involve T-cell lymphoma or do not use bexarotene, and the literature is mostly general reviews and case reports. The prediction is therefore a hypothesis, not a supported indication.
For comparison, the same evidence pack’s rank 2 prediction, Sezary syndrome (a leukemic CTCL variant), has far stronger support. It has several completed Phase 2 bexarotene combination trials and one terminated Phase 3 trial (NCT00056056), and is scored L1.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01134341 | Phase 1 | Completed | 34 | Dose-finding of pralatrexate plus oral bexarotene in relapsed or refractory CTCL. Population is T-cell, so the link to B-cell lymphoma is indirect. |
| NCT05106192 | N/A | Withdrawn | 0 | Needle-free triamcinolone injection in primary cutaneous lymphoma plaques (T- and B-cell). No bexarotene and no data generated. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31466585 | 2019 | Review | Dermatologic Clinics | Diagnosis and management of cutaneous B-cell lymphomas. Treatment guidelines are limited and localized therapies are preferred. |
| 34059248 | 2021 | Review | Medical Clinics of North America | Overview of cutaneous T- and B-cell lymphomas. Cutaneous B-cell lymphomas have fewer variants. |
| 14616487 | 2003 | Review | Australasian Journal of Dermatology | Management of primary cutaneous lymphomas. Classical options include retinoids among many others. |
| 19786826 | 2009 | Review | Skin Pharmacology and Physiology | New skin-directed therapies for cutaneous T- and B-cell lymphomas. |
| 31932947 | 2020 | Review | Der Pathologe | Cutaneous lymphoma overview. Bexarotene is named as a systemic option for later-stage MF and Sézary syndrome (T-cell), not B-cell. |
| 31511903 | 2019 | Review | Der Hautarzt | Same content as above. Bexarotene is cited for T-cell disease. |
| 20806174 | 2010 | Review | Therapeutische Umschau | Cutaneous lymphomas and the WHO/EORTC classification. |
| 22031653 | 2011 | Case report | Dermatology Online Journal | Recurrent localized primary cutaneous marginal-zone B-cell lymphoma. No bexarotene involvement. |
| 29881891 | 2018 | Case series (n=163) | Der Hautarzt | Primary cutaneous lymphoma case series from routine clinical practice. |
| 15861527 | 2005 | Case report | Croatian Medical Journal | EBV-associated cutaneous B-cell lymphoma in a mycosis fungoides patient, treated with topical acyclovir. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA021055 | Targretin | Capsule, liquid filled | Bausch Health US, LLC |
| ANDA203174 | Bexarotene | Capsule, liquid filled | Mylan Pharmaceuticals Inc. |
| ANDA209886 | Bexarotene | Capsule | Upsher-Smith Laboratories, Inc. |
| ANDA210105 | Bexarotene | Capsule | AvKARE |
| ANDA215398 | Bexarotene | Gel (topical) | Amneal Pharmaceuticals NY LLC |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (rexinoid, RXR agonist) rather than a conventional cytotoxic |
| Myelosuppression Risk | Low to moderate. Neutropenia is reported with the capsules. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Fasting lipids (triglycerides), thyroid function (free T4/TSH), CBC with differential |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Reported in the literature: hypertriglyceridemia (the most frequent adverse effect, often requiring dose reduction or interruption, with higher risk at higher BMI), central hypothyroidism (concomitant levothyroxine is recommended), and neutropenia with the capsules. The gel causes an irritant dermatitis.
No structured warnings, contraindications or drug interaction data were available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The 99.44% TxGNN score is not backed by bexarotene evidence in B-cell disease. The only related trials are a T-cell combination study and a withdrawn trial without bexarotene, and the literature is general reviews and case reports. Evidence is L4 (model prediction plus mechanistic plausibility only). The stronger candidate from this pack is Sezary syndrome (CTCL).
To proceed, the following is needed:
- Preclinical evidence that RXR activation affects B-cell lymphoma cells (marginal zone, follicle center, large B-cell)
- Any clinical case series or trial with bexarotene in primary cutaneous B-cell lymphoma
- The original indication and mechanism of action from the package insert or DrugBank
- FDA package insert warnings and contraindications for safety screening
- A route-of-administration comparison (oral capsule vs topical gel) against the lesion type
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.